January 5, 2018 09:05 AM ESTUpdated 09:51 AM
Peer Review

Sanuj Ravin­dran to lead Pelle­Pharm as CEO; Paul Hast­ings leaves On­coMed; Mod­er­na taps John Mendlein as pres­i­dent

Amber Tong

→ A new pres­i­dent and CEO, Sanuj Ravin­dran, will lead Pelle­Pharm in­to this year’s Phase III tri­al for its skin can­cer drug. Pelle­Pharm, which spe­cial­izes …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

Bris­tol My­ers re­veals more job cuts in New Jer­sey

Mer­ck halts Phase 3 tri­al with PAH drug Win­re­vair fol­low­ing pos­i­tive in­ter­im da­ta 

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Gilead buys ex­per­i­men­tal HIV vac­cines from a small Barcelona biotech

A service from the Financial Times